In interview with the Pink Sheet, US FDA Commissioner says the agency needs new ways for in-house talent to more easily rise to supervisory and executive levels.
The next Janet Woodcock may already be working among FDA's rank-and-file staff, waiting to be discovered. Commissioner Scott Gottlieb is considering what tools are available to ensure that talent is nurtured and rewarded quickly.
In an interview with the Pink Sheet and sister publication Medtech Insight, Gottlieb said one of his priorities for improving...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
